Search results
Results from the WOW.Com Content Network
Blood is a peer-reviewed medical journal published by the American Society of Hematology.It was established by William Dameshek in 1946. The journal changed from semimonthly (24 times annually) to weekly publication at the start of 2009.
The American Society of Hematology (ASH) is a professional organization representing hematologists, founded in 1958. Its annual meeting is held in December of every year and has attracted more than 30,000 attendees. [ 1 ]
Gary Herbert Lyman is an American academic hematologist, medical oncologist, and cancer researcher. [1]Lyman is most known for his efforts in managing the adverse effects of cancer treatment including neutropenia and thrombosis among other toxicities along with establishing the clinical application of colony-stimulating factors and oral anticoagulants.
American Journal of Hematology is an academic journal devoted to the coverage of blood diseases. It has been published since 1976. The editor-in-chief is Carlo Brugnara (Harvard Medical School). [1] According to the Journal Citation Reports, the journal has a 2022 impact factor of 12.8, ranking it 7th out of 76 journals in the category ...
And if you were at the ASH Congress, the American Society of Hematology, you saw some of the early tantalizing data where in early lines of therapy front -- first, second line of myeloma, we're ...
The American Society of Clinical Oncology (ASCO) is a professional organization representing physicians of all oncology sub-specialties who care for people with cancer. Founded in 1964 by Fred Ansfield, Harry Bisel, Herman Freckman, Arnoldus Goudsmit, Robert Talley, William Wilson, and Jane C. Wright, it has nearly 45,000 members worldwide.
Cancer is a biweekly peer-reviewed scientific journal covering oncology. The journal was established in 1948. It is an official journal of the American Cancer Society and is published by Wiley-Blackwell on behalf of the society. The first editor-in-chief was Fred W. Stewart, who held that position until 1961.
We expect Medicare Part D redesign to have a negative impact to sales of approximately $400 million, primarily affecting Winrevair and our portfolio of small molecule oncology products, including ...